Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer
Abstract
:1. Introduction
2. Results
2.1. TNBC Cells with the Basal B-Like Phenotype Exhibit Gene Amplification and Overexpression of Aurora A and Bcl-xL
2.2. Inhibition of Aurora A and BCL2L1 Reduces Invasion of Basal B TNBC Cell Lines
2.3. High AURKA and BCL2L1 Expression Correlates with Poor Clinical Outcome in TNBC
3. Discussion
4. Materials and Methods
4.1. Cell Line Culture
4.2. DNA Extraction and CNV Assay
4.3. Protein Extraction and Western Blot
4.4. Immunocytochemistry
4.5. Aurora A Inhibition with Alisertib
4.6. BCL2L1 siRNA Knockdown
4.7. Cell Proliferation Assay
4.8. Cell Invasion Assay
4.9. Kaplan–Meier Plotting
4.10. Statistical Analysis
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 2022, 72, 7–33. [Google Scholar] [CrossRef] [PubMed]
- Association of the Nordic Cancer Registries; Danish Cancer Society; Danckert, B.; Ferlay, J.; Engholm, G.; Hansen, H.L.; Johannesen, T.B.; Khan, S.; Køtlum, J.E.; Ólafsdóttir, E.; et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries. Available online: http://www.ancr.nu (accessed on 29 August 2022).
- Malorni, L.; Shetty, P.B.; De Angelis, C.; Hilsenbeck, S.; Rimawi, M.F.; Elledge, R.; Osborne, C.K.; De Placido, S.; Arpino, G. Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res. Treat. 2012, 136, 795–804. [Google Scholar] [CrossRef] [PubMed]
- Bauer, K.R.; Brown, M.; Cress, R.D.; Parise, C.A.; Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer 2007, 109, 1721–1728. [Google Scholar] [CrossRef] [PubMed]
- Denkert, C.; Liedtke, C.; Tutt, A.; von Minckwitz, G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet 2017, 389, 2430–2442. [Google Scholar] [CrossRef]
- Ehmsen, S.; Hansen, L.T.; Bak, M.; Brasch-Andersen, C.; Ditzel, H.J.; Leth-Larsen, R. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype. Int. J. Cancer 2015, 137, 2093–2103. [Google Scholar] [CrossRef]
- Gonzalez-Angulo, A.M.; Timms, K.M.; Liu, S.; Chen, H.; Litton, J.K.; Potter, J.; Lanchbury, J.S.; Stemke-Hale, K.; Hennessy, B.T.; Arun, B.K.; et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin. Cancer Res. 2011, 17, 1082–1089. [Google Scholar] [CrossRef]
- Bardia, A.; Tolaney, S.M.; Loirat, D.; Punie, K.; Oliveira, M.; Rugo, H.S.; Brufsky, A.; Kalinsky, K.; Cortes, J.; O’Shaughnessy, J.; et al. ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC). Ann. Oncol. 2020, 31, S1149–S1150. [Google Scholar] [CrossRef]
- Bardia, A.; Hurvitz, S.A.; Tolaney, S.M.; Loirat, D.; Punie, K.; Oliveira, M.; Brufsky, A.; Sardesai, S.D.; Kalinsky, K.; Zelnak, A.B.; et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N. Engl. J. Med. 2021, 384, 1529–1541. [Google Scholar] [CrossRef]
- Schmid, P.; Cortes, J.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y.H.; Hui, R.; Harbeck, N.; et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N. Engl. J. Med. 2020, 382, 810–821. [Google Scholar] [CrossRef] [PubMed]
- Sotiriou, C.; Neo, S.Y.; McShane, L.M.; Korn, E.L.; Long, P.M.; Jazaeri, A.; Martiat, P.; Fox, S.B.; Harris, A.L.; Liu, E.T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. USA 2003, 100, 10393–10398. [Google Scholar] [CrossRef] [Green Version]
- Keller, P.J.; Lin, A.F.; Arendt, L.M.; Klebba, I.; Jones, A.D.; Rudnick, J.A.; DiMeo, T.A.; Gilmore, H.; Jefferson, D.M.; Graham, R.A.; et al. Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines. Breast Cancer Res. 2010, 12, R87. [Google Scholar] [CrossRef] [PubMed]
- Neve, R.M.; Chin, K.; Fridlyand, J.; Yeh, J.; Baehner, F.L.; Fevr, T.; Clark, L.; Bayani, N.; Coppe, J.P.; Tong, F.; et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10, 515–527. [Google Scholar] [CrossRef] [PubMed]
- Opyrchal, M.; Gil, M.; Salisbury, J.L.; Goetz, M.P.; Suman, V.; Degnim, A.; McCubrey, J.; Haddad, T.; Iankov, I.; Kurokawa, C.B.; et al. Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells. Oncotarget 2017, 8, 91803–91816. [Google Scholar] [CrossRef] [PubMed]
- Tayyar, Y.; Jubair, L.; Fallaha, S.; McMillan, N.A.J. Critical risk-benefit assessment of the novel anti-cancer aurora a kinase inhibitor alisertib (MLN8237): A comprehensive review of the clinical data. Crit. Rev. Oncol. Hematol. 2017, 119, 59–65. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.-G.; McKinney, K.Q.; Hwang, S.-I. Chapter 10—Proteomic Differences and Linkages between Chemoresistance and Metastasis of Pancreatic Cancer Using Knowledge-Based Pathway Analysis. In Molecular Diagnostics and Treatment of Pancreatic Cancer; Azmi, A.S., Ed.; Academic Press: Oxford, UK, 2014; pp. 221–244. [Google Scholar]
- Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15, 178–196. [Google Scholar] [CrossRef]
- Bao, L.; Qian, Z.; Lyng, M.B.; Wang, L.; Yu, Y.; Wang, T.; Zhang, X.; Yang, H.; Brunner, N.; Wang, J.; et al. Coexisting genomic aberrations associated with lymph node metastasis in breast cancer. J. Clin. Investig. 2018, 128, 2310–2324. [Google Scholar] [CrossRef]
- D’Assoro, A.B.; Liu, T.; Quatraro, C.; Amato, A.; Opyrchal, M.; Leontovich, A.; Ikeda, Y.; Ohmine, S.; Lingle, W.; Suman, V.; et al. The mitotic kinase Aurora—A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERalpha(+) breast cancer cells. Oncogene 2014, 33, 599–610. [Google Scholar] [CrossRef]
- Keitel, U.; Scheel, A.; Thomale, J.; Halpape, R.; Kaulfuss, S.; Scheel, C.; Dobbelstein, M. Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation. Oncotarget 2014, 5, 11778–11791. [Google Scholar] [CrossRef]
- Nikonova, A.S.; Astsaturov, I.; Serebriiskii, I.G.; Dunbrack, R.L., Jr.; Golemis, E.A. Aurora A kinase (AURKA) in normal and pathological cell division. Cell. Mol. Life Sci. 2013, 70, 661–687. [Google Scholar]
- Zhang, J.; Li, B.; Yang, Q.; Zhang, P.; Wang, H. Prognostic value of Aurora kinase A (AURKA) expression among solid tumor patients: A systematic review and meta-analysis. Jpn. J. Clin. Oncol. 2015, 45, 629–636. [Google Scholar] [CrossRef]
- Weier, H.U.; Mao, J.H. Meta-analysis of Aurora Kinase A (AURKA) Expression Data Reveals a Significant Correlation between Increased AURKA Expression and Distant Metastases in Human ER-positive Breast Cancers. J. Data Min. Genom. Proteom. 2013, 4, 127. [Google Scholar]
- Clinical Trials. Available online: https://clinicaltrials.gov/ (accessed on 1 July 2018).
- Ren, B.J.; Zhou, Z.W.; Zhu, D.J.; Ju, Y.L.; Wu, J.H.; Ouyang, M.Z.; Chen, X.W.; Zhou, S.F. Alisertib Induces Cell Cycle Arrest, Apoptosis, Autophagy and Suppresses EMT in HT29 and Caco-2 Cells. Int. J. Mol. Sci. 2015, 17, 41. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liewer, S.; Huddleston, A. Alisertib: A review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors. Expert. Opin. Investig. Drugs 2018, 27, 105–112. [Google Scholar] [CrossRef] [PubMed]
- Popgeorgiev, N.; Jabbour, L.; Gillet, G. Subcellular Localization and Dynamics of the Bcl-2 Family of Proteins. Front. Cell Dev. Biol. 2018, 6, 13. [Google Scholar] [CrossRef] [PubMed]
- Gabellini, C.; Trisciuoglio, D.; Del Bufalo, D. Non-canonical roles of Bcl-2 and Bcl-xL proteins: Relevance of BH4 domain. Carcinogenesis 2017, 38, 579–587. [Google Scholar] [CrossRef]
- Shtivelman, E. A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Oncogene 1997, 14, 2167–2173. [Google Scholar] [CrossRef]
- Takaoka, A.; Adachi, M.; Okuda, H.; Sato, S.; Yawata, A.; Hinoda, Y.; Takayama, S.; Reed, J.C.; Imai, K. Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene 1997, 14, 2971–2977. [Google Scholar] [CrossRef]
- Glinsky, G.V.; Glinsky, V.V. Apoptosis amd metastasis: A superior resistance of metastatic cancer cells to programmed cell death. Cancer Lett. 1996, 101, 43–51. [Google Scholar] [CrossRef]
- Fernandez, Y.; Espana, L.; Manas, S.; Fabra, A.; Sierra, A. Bcl-xL promotes metastasis of breast cancer cells by induction of cytokines resistance. Cell Death Differ. 2000, 7, 350–359. [Google Scholar] [CrossRef]
- Dai, X.; Cheng, H.; Bai, Z.; Li, J. Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping. J. Cancer 2017, 8, 3131–3141. [Google Scholar] [CrossRef]
- Gluz, O.; Liedtke, C.; Gottschalk, N.; Pusztai, L.; Nitz, U.; Harbeck, N. Triple-negative breast cancer—Current status and future directions. Ann. Oncol. 2009, 20, 1913–1927. [Google Scholar] [CrossRef] [PubMed]
- Rakha, E.A.; El-Rehim, D.A.; Paish, C.; Green, A.R.; Lee, A.H.; Robertson, J.F.; Blamey, R.W.; Macmillan, D.; Ellis, I.O. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur. J. Cancer 2006, 42, 3149–3156. [Google Scholar] [CrossRef] [PubMed]
- Schneider, B.P.; Winer, E.P.; Foulkes, W.D.; Garber, J.; Perou, C.M.; Richardson, A.; Sledge, G.W.; Carey, L.A. Triple-negative breast cancer: Risk factors to potential targets. Clin. Cancer Res. 2008, 14, 8010–8018. [Google Scholar] [CrossRef] [PubMed]
- Liedtke, C.; Mazouni, C.; Hess, K.R.; Andre, F.; Tordai, A.; Mejia, J.A.; Symmans, W.F.; Gonzalez-Angulo, A.M.; Hennessy, B.; Green, M.; et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26, 1275–1281. [Google Scholar] [CrossRef]
- Bell, R.; Barraclough, R.; Vasieva, O. Gene Expression Meta-Analysis of Potential Metastatic Breast Cancer Markers. Curr. Mol. Med. 2017, 17, 200–210. [Google Scholar] [CrossRef]
- Gayle, S.S.; Sahni, J.M.; Webb, B.M.; Weber-Bonk, K.L.; Shively, M.S.; Spina, R.; Bar, E.E.; Summers, M.K.; Keri, R.A. Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells. J. Biol. Chem. 2019, 294, 875–886. [Google Scholar] [CrossRef]
- Castellanet, O.; Ahmad, F.; Vinik, Y.; Mills, G.B.; Habermann, B.; Borg, J.P.; Lev, S.; Lamballe, F.; Maina, F. BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators. Theranostics 2021, 11, 9180–9197. [Google Scholar] [CrossRef]
- Murai, S.; Matuszkiewicz, J.; Okuzono, Y.; Miya, H.; De Jong, R. Aurora B Inhibitor TAK-901 Synergizes with BCL-xL Inhibition by Inducing Active BAX in Cancer Cells. Anticancer Res. 2017, 37, 437–444. [Google Scholar] [CrossRef]
- Shah, O.J.; Lin, X.; Li, L.; Huang, X.; Li, J.; Anderson, M.G.; Tang, H.; Rodriguez, L.E.; Warder, S.E.; McLoughlin, S.; et al. Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization. Proc. Natl. Acad. Sci. USA 2010, 107, 12634–12639. [Google Scholar] [CrossRef]
- Olopade, O.I.; Adeyanju, M.O.; Safa, A.R.; Hagos, F.; Mick, R.; Thompson, C.B.; Recant, W.M. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J. Sci. Am. 1997, 3, 230–237. [Google Scholar]
- Xu, J.; Wu, X.; Zhou, W.H.; Liu, A.W.; Wu, J.B.; Deng, J.Y.; Yue, C.F.; Yang, S.B.; Wang, J.; Yuan, Z.Y.; et al. Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancer. PLoS ONE 2013, 8, e56919. [Google Scholar] [CrossRef] [PubMed]
- Nadler, Y.; Camp, R.L.; Schwartz, C.; Rimm, D.L.; Kluger, H.M.; Kluger, Y. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin. Cancer Res. 2008, 14, 4455–4462. [Google Scholar] [CrossRef] [PubMed]
- Siggelkow, W.; Boehm, D.; Gebhard, S.; Battista, M.; Sicking, I.; Lebrecht, A.; Solbach, C.; Hellwig, B.; Rahnenfuhrer, J.; Koelbl, H.; et al. Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients. BMC Cancer 2012, 12, 562. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lundholt, B.K.; Briand, P.; Lykkesfeldt, A.E. Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res. Treat. 2001, 67, 199–214. [Google Scholar] [CrossRef]
- Lanczky, A.; Gyorffy, B. Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation. J. Med. Internet Res. 2021, 23, e27633. [Google Scholar] [CrossRef]
Variable | RFS HR (95% CI) | 1 RFS p | DMFS HR (95% CI) | 1 DMFS p |
---|---|---|---|---|
MKI67 | 0.89 (0.62–1.28) | 0.5373 | 1.05 (0.72–1.53) | 0.799 |
ESR1 | 1.42 (1.02–2) | 0.0407 * | 1.49 (1.02–2.19) | 0.0412 * |
AURKA + BCL2L1 | 1.65 (1.18–2.3) | 0.0036 ** | 1.74 (1.12–2.69) | 0.0134 * |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Skov, N.; Alves, C.L.; Ehmsen, S.; Ditzel, H.J. Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer. Int. J. Mol. Sci. 2022, 23, 10053. https://doi.org/10.3390/ijms231710053
Skov N, Alves CL, Ehmsen S, Ditzel HJ. Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2022; 23(17):10053. https://doi.org/10.3390/ijms231710053
Chicago/Turabian StyleSkov, Natascha, Carla L. Alves, Sidse Ehmsen, and Henrik J. Ditzel. 2022. "Aurora Kinase A and Bcl-xL Inhibition Suppresses Metastasis in Triple-Negative Breast Cancer" International Journal of Molecular Sciences 23, no. 17: 10053. https://doi.org/10.3390/ijms231710053